Abstract:Background: The use of a personalized liver organoid derived from human-induced pluripotent stem cells (HuiPSCs) is advancing the use of in vitro disease models for the design of specific, effective therapies for individuals. Collecting patient peripheral blood cells for HuiPSC generation is preferable because it is less invasive; however, the capability of blood cell-derived HuiPSCs for hepatic differentiation and liver organoid formation remains uncertain. Moreover, the currently available methods for liver organoid formation require a multistep process of cell differentiation or a combination of hepatic endodermal, endothelial and mesenchymal cells, which is a major hurdle for the application of personalized liver organoids in high-throughput testing of drug toxicity and safety. To demonstrate the capability of blood cell-derived HuiPSCs for liver organoid formation without support from endothelial and mesenchymal cells. Methods: The peripheral blood-derived HuiPSCs first differentiated into hepatic endoderm (HE) in two-dimensional (2D) culture on Matrigel-coated plates under hypoxia for 10 days. The HE was then collected and cultured in 3D culture using 50% Matrigel under ambient oxygen. The maturation of hepatocytes was further induced by adding hepatocyte growth medium containing HGF and oncostatin M on top of the 3D culture and incubating the culture for an additional 12-17 days. The function of the liver organoids was assessed using expression analysis of hepatocyte-specific gene and proteins. Albumin (ALB) synthesis, glycogen and lipid storage, and metabolism of indocyanine were evaluated. The spatial distribution of albumin was examined using immunofluorescence and confocal microscopy. Results: CD34+ hematopoietic cell-derived HuiPSCs were capable of differentiating into definitive endoderm expressing SOX17 and FOXA2, hepatic endoderm expressing FOXA2, hepatoblasts expressing AFP and hepatocytes expressing ALB. On day 25 of the 2D culture, cells expressed SOX17, FOXA2, AFP and ALB, indicating the presence of cellular heterogeneity. In contrast, the hepatic endoderm spontaneously formed a spherical, hollow structure in a 3D culture of 50% Matrigel, whereas hepatoblasts and hepatocytes could not form. Microscopic observation showed a single layer of polygonal-shaped cells arranged in a 3D structure. The hepatic endoderm-derived organoid synthesis ALB at a higher level than the 2D culture but did not express definitive endoderm-specific SOX17, indicating the greater maturity of the hepatocytes in the liver organoids. Confocal microscopic images and quantitative ELISA confirmed albumin synthesis in the cytoplasm of the liver organoid and its secretion. Overall, 3D culture of the hepatic endoderm is a relatively fast, simple, and less laborious way to generate liver organoids from HuiPSCs that is more physiologically relevant than 2D culture.

hESCs-derived organoids achieve liver zonation by LSEC modulation

Self-Assembled Generation of Multi-zonal Liver Organoids from Human Pluripotent Stem Cells

Generation of multilineage liver organoids with luminal vasculature and bile ducts from human pluripotent stem cells via modulation of Notch signaling

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Human Liver Organoid: Modeling Liver Steatosis and Beyond

In Situ Differentiation and Generation of Functional Liver Organoids from Human Ipscs in a 3D Perfusable Chip System.

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

A Novel 3d Liver Organoid System for Elucidation of Hepatic Glucose Metabolism

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Liver Organoids: Established Tools for Disease Modeling and Drug Development

Endothelial Cells Instruct Liver Specification of Embryonic Stem Cell-Derived Endoderm Through Endothelial VEGFR2 Signaling and Endoderm Epigenetic Modifications.

Development of a High-Throughput Micropatterned Agarose Scaffold for Consistent and Reproducible Hpsc-Derived Liver Organoids.

Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response

Liver Organoids: Formation Strategies and Biomedical Applications

Generation of hepatobiliary organoids from human induced pluripotent stem cells.

Generation of human liver organoids from pluripotent stem cell-derived hepatic endoderms

Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System

Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids